Drake Insulin / T2D Hypothesized Full Protocol

What Drake Has Actually Said Publicly

Drake has not issued a formal public statement about using any anti-diabetic or weight-loss medication. What exists in the record is a single, unambiguous lyric reference and a documented pattern of body-composition change that observers noted beginning in 2022.

The Lyric Reference

In the track "Rich Flex," released November 2022 on the joint album "Her Loss" (Drake and 21 Savage), Drake raps a line that name-checks Ozempic in the context of physical appearance. The line does not constitute a medical disclosure. It could reflect personal experience, cultural commentary on the drug's rising celebrity profile, or both. Journalists at outlets including Rolling Stone and TMZ treated it as a winking admission. Clinicians should treat it as unverified public speech.

Body-Composition Observations

Paparazzi photographs from 2021 through 2024 show a visible reduction in truncal adiposity. Drake's face, jaw, and abdomen appear leaner across this window. These changes are consistent with, but not proof of, GLP-1 receptor agonist use. Similar changes occur with caloric restriction, increased resistance training, or bariatric procedures. Without metabolic labs, DEXA scans, or a personal statement, any single explanation remains speculative.

What He Has Not Said

Drake has not confirmed a type 2 diabetes diagnosis, a prediabetes diagnosis, or a prescription for any semaglutide product. The inference that he uses a GLP-1 agent rests on circumstantial public evidence only.

Why GLP-1 Receptor Agonists Are the Hypothesized Agent

Semaglutide is the molecule most logically centered in any hypothesized Drake protocol, given the lyric reference to Ozempic specifically. Semaglutide is available in two FDA-approved formulations relevant here: Ozempic (semaglutide 0.5 to 2 mg subcutaneous weekly, approved for type 2 diabetes) and Wegovy (semaglutide 2.4 mg subcutaneous weekly, approved for chronic weight management) [1].

Mechanism of Action

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds GLP-1 receptors in the pancreas, gut, and brain. Pancreatic binding stimulates glucose-dependent insulin secretion and suppresses glucagon. Central nervous system binding in the hypothalamus and area postrema reduces appetite and caloric intake [2]. The net result is lower postprandial glucose, slower gastric emptying, and a meaningful reduction in ad-libitum food intake.

The STEP Trial Data

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [3]. The STEP-4 trial (N=803) demonstrated that discontinuing semaglutide after 20 weeks led to weight regain of approximately two-thirds of the lost weight by week 68, underscoring that GLP-1 therapy requires long-term maintenance [4]. For a person of Drake's reported height (approximately 6 feet / 183 cm) and estimated pre-treatment weight in the 195 to 215 lb range, a 14.9% reduction would translate to roughly 29 to 32 lbs of weight loss over 68 weeks.

Tirzepatide as an Alternative Hypothesis

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist approved by the FDA in May 2022 for type 2 diabetes and November 2023 for obesity [5]. The SURMOUNT-1 trial (N=2,539) reported 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg versus 3.1% placebo (P<0.001) [6]. Given that Drake's lyric specifies "Ozempic" by name rather than a generic drug class, semaglutide remains the more parsimonious hypothesis. Tirzepatide is noted here for completeness only.

Hypothesized Full Protocol

The following protocol is constructed by the HealthRX medical team as a clinical thought experiment. Every element is labeled as inference. Nothing here reflects confirmed information about Drake's actual medical care.

Hypothesized Step 1: Baseline Metabolic Workup

Any responsible prescriber initiating a GLP-1 agent would first obtain a metabolic panel. For a male patient in his mid-to-late 30s with visible central adiposity, standard practice per the American Association of Clinical Endocrinology (AACE) 2023 Obesity Algorithm includes: fasting glucose, HbA1c, fasting lipid panel, thyroid-stimulating hormone (TSH), liver function tests, and a complete blood count [7]. If HbA1c falls between 5.7% and 6.4%, the patient is classified as prediabetic per ADA criteria [8]. If HbA1c reaches 6.5% or higher on two separate occasions, type 2 diabetes is the diagnosis.

Drake's visible body habitus in earlier photographs is consistent with a BMI in the 27 to 30 range, which falls within the "overweight" category. A BMI of 27 or higher with at least one weight-related comorbidity meets FDA labeling criteria for Wegovy (semaglutide 2.4 mg) [1].

Hypothesized Step 2: Semaglutide Dose Titration

Standard semaglutide titration for weight management (Wegovy) follows a fixed schedule to minimize gastrointestinal side effects [1]:

• Weeks 1 to 4: 0.25 mg subcutaneous once weekly
• Weeks 5 to 8: 0.5 mg subcutaneous once weekly
• Weeks 9 to 12: 1.0 mg subcutaneous once weekly
• Weeks 13 to 16: 1.7 mg subcutaneous once weekly
• Week 17 onward: 2.4 mg subcutaneous once weekly (maintenance)

If the hypothesized agent is Ozempic (the T2D formulation), the maintenance ceiling is 2.0 mg weekly. Tolerability at each step determines whether titration proceeds on schedule or is extended by four weeks. Nausea affects approximately 44% of patients at some point during titration; vomiting affects roughly 24% [3].

Hypothesized Step 3: Adjunct Medications

A clinician managing a celebrity patient with metabolic concerns and a desire for body-composition optimization might add several adjuncts to a GLP-1 backbone:

Metformin 500 to 1,000 mg twice daily. For a patient with prediabetes or early T2D, metformin remains the first-line oral agent per ADA Standards of Medical Care 2024 [8]. It has a 60-year safety record, costs under $10/month as generic, and may independently reduce cardiovascular risk [9].

A statin. The ACC/AHA Pooled Cohort Equation places a 38-year-old male with a BMI near 28 and no other risk factors at a 10-year ASCVD risk below 7.5%, which sits below the threshold for routine statin initiation [10]. If triglycerides or LDL are elevated on baseline labs, a moderate-intensity statin such as atorvastatin 20 to 40 mg daily would be standard.

Berberine 500 mg three times daily. This is speculative. Berberine has shown modest glucose-lowering and lipid-lowering effects in meta-analyses, though evidence quality is lower than for metformin [11]. It is available over the counter and is commonly self-administered by health-conscious individuals.

Hypothesized Step 4: Lifestyle Integration

The STEP-1 trial's semaglutide arm was paired with a 500-calorie-per-day deficit diet and 150 minutes per week of moderate-intensity exercise [3]. Drake's public social media posts frequently show gym sessions, basketball, and swimming. These activities align with the physical activity component of standard GLP-1 adjunct therapy. Resistance training during GLP-1-assisted weight loss is particularly important: a 2022 analysis in Obesity found that adding resistance training to a GLP-1 regimen preserved lean mass significantly better than aerobic activity alone [12].

Hypothesized Step 5: Monitoring and Follow-Up

Per AACE guidelines, patients on GLP-1 therapy for weight management should have HbA1c, fasting lipids, and kidney function rechecked at 3 months and 6 months after initiation, then annually if stable [7]. Blood pressure monitoring every visit is standard, given semaglutide's modest but consistent reductions in systolic blood pressure observed in the STEP trials (approximately 3 to 5 mmHg mean reduction) [3].

Thyroid monitoring deserves specific mention. Semaglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent data [1]. The clinical significance in humans remains uncertain, but patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome are contraindicated for GLP-1 therapy. A baseline TSH and a clinical history review are mandatory before prescribing.

Is There Any Evidence of Type 2 Diabetes?

No public record confirms a T2D diagnosis for Drake. The lyric reference to Ozempic is as consistent with off-label weight-management use as with T2D management. Off-label use of Ozempic for weight loss in patients without diabetes became widespread after the STEP trial publications and before Wegovy's full commercial availability in 2022 [13].

Prevalence Context

Type 2 diabetes affects approximately 11.6% of the U.S. Adult population as of 2023 CDC estimates [14]. Prediabetes affects a further 38% of U.S. Adults, the majority of whom are undiagnosed [14]. A 38-year-old Black man with central adiposity faces an elevated risk profile: Black Americans have a 60% higher age-adjusted prevalence of diagnosed diabetes compared to non-Hispanic white Americans, per CDC surveillance data [14].

What a Positive Diagnosis Would Change Clinically

If Drake does have T2D, Ozempic (not Wegovy) would be the on-label product. The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) demonstrated that semaglutide 0.5 mg and 1.0 mg weekly reduced the risk of major adverse cardiovascular events (MACE) by 26% versus placebo in patients with T2D and established cardiovascular disease or high cardiovascular risk (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority; P=0.02 for superiority) [15]. The ADA 2024 Standards of Medical Care recommends GLP-1 receptor agonists as preferred agents in T2D patients with established cardiovascular disease or high cardiovascular risk, regardless of baseline HbA1c [8].

Clinical Commentary: The Ethics of Celebrity Protocol Speculation

The HealthRX medical team acknowledges that constructing a hypothesized protocol for a named public figure carries ethical weight. We have followed three principles in this article.

First, every clinical inference is labeled as inference. No statement above claims to reflect Drake's actual care. Second, this article does not diagnose Drake. It maps observable public evidence onto established clinical frameworks. Third, the clinical information here is accurate and useful regardless of whether Drake uses any of these agents. A reader researching semaglutide, metformin, or T2D workup protocols will find evidence-based information that applies to their own situation.

As the ADA Standards of Medical Care 2024 states directly: "Providers should offer individualized, patient-centered care that considers the patient's preferences, values, and social context" [8]. That principle applies whether the patient is a global recording artist or anyone else walking into a primary care office.

Who Actually Qualifies for Semaglutide?

FDA labeling for Wegovy specifies two eligibility criteria: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, obstructive sleep apnea, or cardiovascular disease) [1]. For Ozempic, the indication is adults with type 2 diabetes requiring glycemic control, with a secondary indication for cardiovascular risk reduction in T2D patients with established heart disease [15].

Clinicians should screen for contraindications before prescribing. These include personal or family history of MEN2 or medullary thyroid carcinoma, current or recent pancreatitis, and pregnancy [1]. Gallbladder disease risk increases with rapid weight loss on GLP-1 therapy: the STEP-1 trial reported cholelithiasis in 2.6% of semaglutide patients versus 1.2% placebo [3].

Cost and Access

Wegovy's list price in the United States is approximately $1,349 per month without insurance as of early 2025. Manufacturer coupon programs (Novo Nordisk's NovoCare) can reduce out-of-pocket costs for commercially insured patients. Medicare Part D now covers Wegovy for cardiovascular risk reduction following the SELECT trial results, which showed semaglutide 2.4 mg reduced MACE by 20% in non-diabetic patients with obesity and established cardiovascular disease (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [16]. For patients without cardiovascular disease, coverage remains variable.

Compounded Semaglutide

During the FDA-declared shortage of both Ozempic and Wegovy (2022 to 2024), compounded semaglutide became widely available through telehealth platforms. The FDA removed Wegovy from the shortage list in February 2025 and Ozempic in March 2025. Compounded semaglutide from 503B outsourcing facilities became prohibited for most patients at that point [17]. Patients seeking semaglutide should now work with licensed prescribers to obtain FDA-approved formulations directly.

Interpreting Visible Body-Composition Change Without Lab Data

Visible weight loss in a public figure generates media speculation, but clinicians know that appearance alone cannot distinguish GLP-1 use from caloric restriction, increased training volume, illness, stress, or surgical intervention. A 2023 paper in JAMA Internal Medicine noted that public attribution of celebrity weight loss to GLP-1 drugs has outpaced verified disclosures significantly, creating both demand spikes and stigma concerns [18].

What the Camera Can and Cannot Show

Facial fat loss (buccal fat pad reduction) is a consistent early finding with semaglutide. The drug produces relatively uniform fat loss across compartments, including visceral and subcutaneous. Visible truncal slimming, jaw definition, and neck narrowing are all consistent with the adipose distribution changes seen in STEP trial DEXA substudies [3]. None of these observations confirm drug use in any specific individual.

The "Ozempic Face" Phenomenon

The term "Ozempic face" entered popular culture in 2023, describing the gaunt or hollow appearance some patients develop with rapid GLP-1-assisted weight loss. A dermatology commentary in JAMA Dermatology noted that facial volume loss is not specific to semaglutide but tracks with the rate and magnitude of weight loss across any etiology [19]. Patients losing more than 15% of body weight over 12 months are at higher risk of noticeable facial volume reduction regardless of the method.

Practical Takeaways for Readers Considering a Similar Protocol

Any person considering a GLP-1-based metabolic protocol should take the following concrete steps before starting.

Get a full metabolic panel. Fasting glucose, HbA1c, lipid panel, TSH, LFTs, and CMP are the minimum baseline. This identifies contraindications and sets a benchmark for monitoring.

Work with a licensed clinician. Telehealth prescribers can order labs, review history, and titrate doses appropriately. Self-administering compounded peptides purchased without a prescription carries serious risks including dosing errors, contamination, and missed contraindications.

Plan for the long term. The STEP-4 data [4] are unambiguous: stopping semaglutide leads to weight regain for most patients. A protocol without a maintenance plan is an incomplete protocol.

Patients with a BMI of 27 or higher and at least one metabolic comorbidity can request a GLP-1 consultation through HealthRX. A board-certified physician reviews all cases before any prescription is issued.